Insider Trading activities at Aldeyra Therapeutics, Inc. (ALDX)

Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Aldeyra Therapeutics, Inc. (ALDX) since 2015 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Aldeyra Therapeutics, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1341235.

Total stock buying since 2015: $73,332,207.
Total stock sales since 2015: $6,761,763.
Total stock option exercises since 2015: $164,331.


17 insiders reported insider trading activities at Aldeyra Therapeutics, Inc. (ALDX):
Insider trading activities of Reed Joshua
Insider trading activities of Phillips Gary M.
Insider trading activities of Mcmullin David
Insider trading activities of Greenberg Bruce
Insider trading activities of Alfieri Michael
Insider trading activities of Brady Todd C
Insider trading activities of Douglas Richard
Insider trading activities of Treu Jesse I
Insider trading activities of Machatha Stephen
Insider trading activities of Perceptive Life Sciences Master Fund Ltd
Insider trading activities of Joyce Martin Joseph
Insider trading activities of Bronstein Ben
Insider trading activities of Miller-rich Nancy
Insider trading activities of Walker Neal
Insider trading activities of Edelman Joseph
Insider trading activities of Tulipano Stephen J
Insider trading activities of Clark David J

Table 1. Yearly summary of insider stock purchases, sales, and option exercises at Aldeyra Therapeutics, Inc. (ALDX).
Insider Buying Insider Sales Option Exercises
Year Shares Value Shares Value Shares Value
2025 2,500 $13,250 3,422,073 $4,941,720 0 $0
2024 682,265 $2,768,370 253,082 $851,646 0 $0
2023 509 $5,156 0 $0 297,703 $164,331
2022 1,327,229 $7,563,086 0 $0 0 $0
2021 3,618,834 $37,024,139 0 $0 0 $0
2020 3,240,000 $13,710,000 0 $0 0 $0
2019 145,607 $793,428 96,743 $968,397 0 $0
2017 1,423,476 $6,985,241 0 $0 0 $0
2016 700,000 $3,500,000 0 $0 0 $0
2015 150,265 $969,537 0 $0 0 $0

Table 2. Monthly summary of insider trading at Aldeyra Therapeutics, Inc. (ALDX).
Trading Period Insider Buying Insider Sales Option Exercises
year-month Shares Value Shares Value Shares Value
2025-08 2,500 $13,250 22,073 $113,720 0 $0
2025-04 0 $0 3,400,000 $4,828,000 0 $0
2024-08 0 $0 26,875 $127,279 0 $0
2024-04 682,265 $2,768,370 0 $0 0 $0
2024-03 0 $0 226,207 $724,367 0 $0
2023-09 0 $0 0 $0 278,495 $153,729
2023-08 0 $0 0 $0 9,604 $5,301
2023-06 0 $0 0 $0 9,604 $5,301
2023-04 509 $5,156 0 $0 0 $0
2022-08 963,691 $5,774,280 0 $0 0 $0
2022-07 341,515 $1,714,238 0 $0 0 $0
2022-06 22,023 $74,568 0 $0 0 $0
2021-05 1,200,413 $15,005,290 0 $0 0 $0
2021-01 2,418,421 $22,018,849 0 $0 0 $0
2020-07 3,200,000 $13,600,000 0 $0 0 $0
2020-03 40,000 $110,000 0 $0 0 $0
2019-12 20,000 $101,900 0 $0 0 $0
2019-09 125,607 $691,528 0 $0 0 $0
2019-03 0 $0 96,743 $968,397 0 $0
2017-09 200,000 $1,450,000 0 $0 0 $0
2017-06 296,007 $1,361,632 0 $0 0 $0
2017-02 927,469 $4,173,609 0 $0 0 $0
2016-05 700,000 $3,500,000 0 $0 0 $0
2015-10 150,265 $969,537 0 $0 0 $0

Table 3. Detailed insider trading at Aldeyra Therapeutics, Inc. (ALDX)
  Trade Date   Insider Name Trade Type     Shares       Price ($)   Value ($)
2025-08-13 Alfieri Michael (Principal Financial Officer) Buy 2,500 5.30 13,250
2025-08-11 Machatha Stephen (Chief Development Officer) Sale 22,073 5.15 113,720
2025-04-03 Edelman Joseph (10% Owner) Sale 3,400,000 1.42 4,828,000
2024-08-12 Greenberg Bruce (See Remarks) Sale 10,834 4.74 51,309
2024-08-12 Machatha Stephen (Chief Development Officer) Sale 16,041 4.74 75,970
2024-04-05 Edelman Joseph (10% Owner) Buy 37,712 4.74 178,754
2024-04-04 Edelman Joseph (10% Owner) Buy 140,281 4.67 655,112
2024-04-03 Edelman Joseph (10% Owner) Buy 309,847 4.09 1,267,274
2024-04-02 Edelman Joseph (10% Owner) Buy 186,051 3.44 640,015
2024-04-01 Edelman Joseph (10% Owner) Buy 8,374 3.25 27,215
2024-03-12 Machatha Stephen (Chief Development Officer) Sale 11,537 3.16 36,503
2024-03-12 Brady Todd C (President and CEO) Sale 85,324 3.05 260,238
2024-03-11 Greenberg Bruce (See Remarks) Sale 13,201 3.41 44,962
2024-03-11 Machatha Stephen (Chief Development Officer) Sale 18,231 3.41 62,094
2024-03-11 Brady Todd C (President and CEO) Sale 97,914 3.27 320,570
2023-09-07 Brady Todd C (President and CEO) Option Ex 273,058 .55 150,728
2023-09-07 Phillips Gary M. Option Ex 5,437 .55 3,001
2023-08-22 Walker Neal Option Ex 9,604 .55 5,301
2023-06-27 Bronstein Ben (Director) Option Ex 9,604 .55 5,301
2023-04-12 Miller-rich Nancy Buy 509 10.13 5,156
2022-08-10 Edelman Joseph (10% Owner) Buy 15,000 7.85 117,750
2022-08-09 Edelman Joseph (10% Owner) Buy 100,000 7.50 750,000
2022-08-08 Edelman Joseph (10% Owner) Buy 97,000 7.24 702,280
2022-08-04 Edelman Joseph (10% Owner) Buy 95,100 6.17 586,767
2022-08-03 Edelman Joseph (10% Owner) Buy 100,000 5.84 584,000
2022-08-02 Edelman Joseph (10% Owner) Buy 412,406 5.59 2,305,349
2022-08-01 Edelman Joseph (10% Owner) Buy 144,185 5.05 728,134
2022-07-29 Edelman Joseph (10% Owner) Buy 222,123 5.03 1,117,278
2022-07-28 Edelman Joseph (10% Owner) Buy 119,392 5.00 596,960
2022-06-23 Brady Todd C (President and CEO) Buy 17,700 3.36 59,542
2022-06-23 Joyce Martin Joseph (Director) Buy 4,323 3.48 15,026
2021-05-03 Miller-rich Nancy Buy 413 12.81 5,290
2021-05-03 Edelman Joseph (10% Owner) Buy 1,200,000 12.50 15,000,000
2021-01-19 Edelman Joseph (10% Owner) Buy 1,368,421 9.50 12,999,999
2021-01-08 Edelman Joseph (10% Owner) Buy 550,000 9.01 4,953,850
2021-01-07 Edelman Joseph (10% Owner) Buy 500,000 8.13 4,065,000
2020-07-09 Edelman Joseph (10% Owner) Buy 3,200,000 4.25 13,600,000
2020-03-16 Douglas Richard (Director) Buy 40,000 2.75 110,000
2019-12-16 Brady Todd C (President and CEO) Buy 20,000 5.09 101,900
2019-09-30 Brady Todd C (President and CEO) Buy 8,710 5.68 49,481
2019-09-23 Brady Todd C (President and CEO) Buy 8,680 5.81 50,430
2019-09-18 Brady Todd C (President and CEO) Buy 14,288 5.91 84,470
2019-09-17 Bronstein Ben (Director) Buy 1,700 5.85 9,945
2019-09-16 Brady Todd C (President and CEO) Buy 3,000 6.03 18,090
2019-09-13 Brady Todd C (President and CEO) Buy 10,000 5.79 57,900
2019-09-13 Douglas Richard (Director) Buy 5,000 6.00 30,000
2019-09-12 Joyce Martin Joseph (Director) Buy 1,700 5.86 9,963
2019-09-12 Douglas Richard (Director) Buy 10,000 6.03 60,279
2019-09-11 Douglas Richard (Director) Buy 10,000 5.75 57,530
2019-09-10 Brady Todd C (President and CEO) Buy 10,000 5.39 53,940
2019-09-10 Douglas Richard (Director) Buy 10,000 5.09 50,860
2019-09-09 Brady Todd C (President and CEO) Buy 10,000 4.89 48,890
2019-09-09 Douglas Richard (Director) Buy 10,000 4.91 49,109
2019-09-06 Clark David J (Chief Medical Officer) Buy 5,000 5.06 25,310
2019-09-05 Reed Joshua (Chief Financial Officer) Buy 3,200 4.71 15,072
2019-09-05 Mcmullin David (Chief Commerical Officer) Buy 4,329 4.68 20,259
2019-03-26 Treu Jesse I (Director) Sale 96,743 10.01 968,397
2017-09-19 Edelman Joseph (10% Owner) Buy 200,000 7.25 1,450,000
2017-06-30 Edelman Joseph (10% Owner) Buy 296,007 4.60 1,361,632
2017-02-17 Bronstein Ben (Director) Buy 4,444 4.50 19,998
2017-02-17 Brady Todd C (President and CEO) Buy 22,223 4.50 100,003
2017-02-17 Tulipano Stephen J (Chief Financial Officer) Buy 3,333 4.50 14,998
2017-02-17 Joyce Martin Joseph (Director) Buy 4,444 4.50 19,998
2017-02-14 Perceptive Life Sciences Master Fund Ltd Buy 893,025 4.50 4,018,612
2016-05-26 Perceptive Life Sciences Master Fund Ltd Buy 700,000 5.00 3,500,000
2015-10-28 Perceptive Life Sciences Master Fund Ltd Buy 45,100 6.50 293,150
2015-10-26 Perceptive Life Sciences Master Fund Ltd Buy 50,000 6.46 323,150
2015-10-22 Perceptive Life Sciences Master Fund Ltd Buy 18,020 6.47 116,661
2015-10-20 Perceptive Life Sciences Master Fund Ltd Buy 37,145 6.37 236,576

Insider trading activities including stock purchases, stock sales, and option exercises of ALDX listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Aldeyra Therapeutics, Inc. (symbol ALDX, CIK number 1341235) see the Securities and Exchange Commission (SEC) website.



©2023, insider-monitor.com. All rights reserved.